Abstract 1717P
Background
Digitalisation of healthcare delivery enhances security, efficiency, and cost-effectiveness. The challenges of transitioning to a modern electronic healthcare system with multiple workflows remain poorly described, especially for early phase trial units. We present our recommendations for digital healthcare transition based on our experiences and outcomes. The Royal Marsden (RM) and Institute of Cancer Research (ICR) Drug Development Unit (DDU) is one of the largest early phase centres in Europe, enrolling ∼300 patients across >60 trials per year, with a dedicated ward, day unit and outpatient clinic.
Methods
In March 2023, RM transitioned to a new healthcare system. DDU adopted a patient centric approach, as per table, with emphasis on safe treatment delivery for patients within the dose-limiting toxicity (DLT) period. Table: 1717P
Planning aims
a) Virtual walk-through trial pathways from referral to discharge b) Patient visits planning and forecast for first 4 weeks. For Week 1, targeted reduction in planned patient attendance by 10% with no patients starting on trial and on-site attendance is prioritised for those within DLT period. c) Staff training < 8 weeks in advance and absences minimised during the transition period d) Managing expectations of patients, staff, and partners e) Daily team meetings to feedback and escalate issues |
Results
All planned trial activities were completed during weeks 1-4; though late IMP dosing up to 21:00 were experienced. Over these weeks, 36 patients were treated within the DLT period, and no safety issues raised. Adaptation pace among staff varied, with reports of fatigue from learning new workflows, improving from Week 4. From Week 5, the number of attendances returned to pre-transition levels.
Conclusions
Major digital transformation projects can be undertaken safely within a phase I trial setting whilst maintaining service delivery, with investments in implementation beyond the technology itself. Staff digital literacy assessments, training, pathway walkthrough, interface familiarisation, managing staff morale are critical for managing such transitions. Extensive planning and focus on the end users are vital in ensuring both short-term delivery and long-term benefits of digital transformation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Institute of Cancer Research and The Royal Marsden Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1716P - Addressing clinical trial disparities in Spain: A digital solution
Presenter: Max Hardy-Werbin
Session: Poster session 23
1718P - Impact of the economic status of the patient's country of residence on the outcome of oncology clinical trials
Presenter: Saki Nishiyama
Session: Poster session 23
1719P - Decentralized clinical trials: Is there a space in Italy?
Presenter: Celeste Cagnazzo
Session: Poster session 23
1720P - Experience in the provision of oncology services immediately after a major disaster
Presenter: Burak Aktas
Session: Poster session 23
1721P - Self-assessment tool and best-practice sharing to support hospitals in improving the quality of multi-disciplinary teams in lung cancer care
Presenter: Ernest Nadal
Session: Poster session 23
1722P - Factors contributing to differences in evidence compliance rate in cancer treatment among second opinion cases
Presenter: Tomomi Sanomachi
Session: Poster session 23
1723P - Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 23
1724P - Improving access to breast cancer diagnosis and treatment through navigation: Evaluation of a one-year pilot project in Botswana
Presenter: Ariane Migeotte
Session: Poster session 23
1725P - Genetic counselling for cancer in EU member states: Review and foundation for consensus recommendations
Presenter: J. Matt McCrary
Session: Poster session 23
1726P - Optimizing oncology drug spending in a cancer centre in Ireland
Presenter: Ruth Kieran
Session: Poster session 23